Essex Investment Management Co. LLC raised its holdings in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 121.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 364,401 shares of the biotechnology company’s stock after acquiring an additional 199,796 shares during the period. Essex Investment Management Co. LLC owned about 0.64% of Infinity Pharmaceuticals worth $988,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Algert Global LLC acquired a new position in shares of Infinity Pharmaceuticals during the second quarter worth about $139,000. Wells Fargo & Company MN boosted its position in shares of Infinity Pharmaceuticals by 83.1% during the first quarter. Wells Fargo & Company MN now owns 192,493 shares of the biotechnology company’s stock worth $404,000 after buying an additional 87,357 shares during the period. Acadian Asset Management LLC boosted its position in shares of Infinity Pharmaceuticals by 95.2% during the second quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock worth $711,000 after buying an additional 181,436 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Infinity Pharmaceuticals by 76.2% during the first quarter. Dimensional Fund Advisors LP now owns 734,272 shares of the biotechnology company’s stock worth $1,542,000 after buying an additional 317,583 shares during the period. 49.28% of the stock is owned by hedge funds and other institutional investors.

INFI stock opened at $2.54 on Friday. Infinity Pharmaceuticals Inc. has a fifty-two week low of $1.65 and a fifty-two week high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.08. As a group, analysts anticipate that Infinity Pharmaceuticals Inc. will post -0.57 earnings per share for the current fiscal year.

Several research firms have recently weighed in on INFI. ValuEngine cut Infinity Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Zacks Investment Research cut Infinity Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 9th.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Story: Yield Curve

Want to see what other hedge funds are holding INFI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infinity Pharmaceuticals Inc. (NASDAQ:INFI).

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.